Prostate Cancer - Identifying and Commercializing First-in-Class Innovation

www.MarketResearchReports.com

Frontier Pharma: Prostate Cancer - Identifying and

Commercializing First-in-Class

Innovation

Category : Healthcare

All logos and Images mentioned on this slide belong to their respective owners.

http://www.marketresearchreports.com/


Introduction to Report

Launch Date: November 30, 2014

Number of Pages: 91

Geography Coverage: Global

Available Format: PDF

Price For Single User License: USD 6,995

Price For Site User License: USD 13,990

Price For Global User License: USD 20,985

Delivery Time: Within 24 Hours (During Working Days)



About the Report

The report analyzes innovation in prostate cancer, in the context of the overall pipeline and current market landscape. In addition, it analyzed the deals landscape surrounding first-in-class products in prostate cancer, and pinpoints opportunities for in-licensing.

The prostate cancer pipeline is among the largest in the pharmaceutical industry with 484 products in active development across all stages.



Key Highlights:

The range of mechanisms of action employed by these compounds is also highly diverse, especially in comparison to the existing market landscape.

More pertinently, the degree and proportion of breakthrough innovations in this pipeline is exceptional; Publisher analysis identified 174 first-in-class programs in the prostate cancer pipeline, acting on 122 first-in-class molecular targets.

This accounts for some 36% of all products with a disclosed molecular target and is reflective of the high degree of innovation in this indication.



Key Highlights Continues…

One of the key trends in oncology and in prostate cancer in particular over the last decade is the clinical and commercial impact of targeted therapies designed to target proteins in signaling pathways that are strongly associated with disease progression.

Our proprietary analyses demonstrate significant levels of differentiation as to how well the first-in-class products and their respective molecular targets align to underlying gene and protein level mutations and dysfunction.

These insights and a detailed review of the available evidence from scientific studies substantiate the perspective that first-in-class-product technology in its own right is not sufficient to offer a compelling scientific and clinical rationale.



Key Highlights Continues…

Analysis has confirmed that 169 of the 174 first-in-class products have not been involved in a licensing or co-development deal.

However, most deals involving first-in-class products were either preclinical or Phase I development, whereas advance-in-class and addition-to-class product deals were typically made in Phases II and III, therefore showing significant differentiation.

These findings have significant strategic implications for both biotech companies seeking to out-license products and firms with an interest in in-licensing first-in-class products with strong clinical and commercial prospects.



Scope:

A brief introduction to prostate cancer, including symptoms, pathophysiology, and overview of pharmacotherapy and treatment algorithms.

The changing molecular target landscape between market and pipeline and particular focal points of innovation in the pipeline.

Comprehensive review of the pipeline for first-in-class therapies, analyzed on the basis of stage of development, molecule type and molecular target.

Identification and assessment of first-in-class molecular targets with a particular focus on early-stage programs of which clinical utility has yet to be evaluated, as well as literature reviews on novel molecular targets.



Report Coverage

1. Executive Summary2. The Case for Innovation in Prostate Cancer3. Clinical and Commercial Landscape4. Assessment of Pipeline Product Innovation5. Signaling Network6. Disease Causation and Innovation Alignment7. First-in-Class Target and Pipeline Program Evaluation8. Deals and Strategic Consolidations9. Appendix

For more details regarding Report coverage see the last slide

All logos and Images mentioned on this slide belong to their respective owners.



Custom Research: Are you an industry professional, entrepreneur,

venture capitalist, investors and organization, then let us know your specific research requirements. Our goal is to cater to your requirements be it for a custom market research project, syndicated research report on a specific market or industry sector, newsletter creation, case study development or anything else related to marketing research.

For Any Customization Related query Visit IdeaCenter @http://www.marketresearchreports.com/idea-center

For regular industry updates subscribe to our newsletter at: http://www.marketresearchreports.com/subscribe-to-newsletter

http://www.marketresearchreports.com/idea-center

http://www.marketresearchreports.com/subscribe-to-newsletter

http://www.marketresearchreports.com/subscribe-to-newsletter



How To Buy This Report?

Visit following URL to see Table of Content and purchase this publication:

http://mrr.cm/44a

About Market Research Reports, Inc.Market Research Reports provides a customized set of reports from reputed Publishers, built on the intelligence available within organizations and leverages on our motto of “Intelligence Redefined”.

Contact : Amitava SenEmail : [email protected]: +1 302-703-7787 (USA) +91-8762746600 (India)

http://mrr.cm/44a

http://mrr.cm/44a

mailto:[email protected]


Prostate Cancer - Identifying and Commercializing First-in-Class Innovation

Healthcare

Transcript of Prostate Cancer - Identifying and Commercializing First-in-Class Innovation